SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).

被引：5
|
作者：
Chi, K. N.
De Bono, J. S.
Higano, C. S.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Inst Canc Res, Sutton, Surrey, England
[3] Royal Marsden Hosp, Sutton, Surrey, England
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS180
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Eigl, B. J.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
    Horgan, Anne M.
    Seruga, Bostjan
    Pond, Greg R.
    Alibhai, Shabbir M.
    Amir, Eitan
    De Wit, Ronald
    Eisenberger, Mario A.
    Tannock, Ian F.
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (02) : 119 - 126
  • [43] Phase II trial of intravenous carboplatin (C), oral everolimus (E), and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trials Consortium study.
    Veeraputhiran, Muthu Kumaran
    Shevrin, Daniel H.
    Stein, Mark N.
    Heilbrun, Lance K.
    Smith, Daryn
    Li, Jing
    Dickow, Brenda
    Heath, Elisabeth I.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
    Chi, Kim N.
    Higano, Celestia S.
    Blumenstein, Brent
    Ferrero, Jean-Marc
    Reeves, James
    Feyerabend, Susan
    Gravis, Gwenaelle
    Merseburger, Axel S.
    Stenzl, Arnulf
    Bergman, Andries M.
    Mukherjee, Som D.
    Zalewski, Pawel
    Saad, Fred
    Jacobs, Cindy
    Gleave, Martin
    de Bono, Johann S.
    LANCET ONCOLOGY, 2017, 18 (04): : 473 - 485
  • [46] A randomized open-label study comparing the docetaxel plus prednisone regimen versus mitoxantrone plus prednisone regimen for metastatic hormone refractory prostate cancer in Chinese population
    Ye, D.
    Sun, Y. H.
    Wei, Q.
    Yao, X.
    Ye, Z. Q.
    Huang, Y. R.
    Zhang, W.
    Yang, Y.
    Tian, Y.
    Na, Y. Q.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S706 - S706
  • [47] C11-acetate PET for docetaxel prednisone (DP) response assessment in castrate-resistant prostate cancer (CRPC)
    Sharma, Nancy
    Menda, Yusuf
    Boles-Ponto, Laura
    Vaena, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [48] C11-acetate PET for docetaxel prednisone (DP) response assessment in castrate-resistant prostate cancer (CRPC).
    Sharma, Nancy
    Menda, Yusuf
    Boles-Ponto, Laura
    Vaena, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer
    Thomson, David
    Charnley, Natalie
    Parikh, Omi
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (05) : 1040 - 1041
  • [50] Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer
    Cornford, Philip
    JOURNAL OF CLINICAL UROLOGY, 2010, 3 (06) : 225 - 230
12345